RBC Capital keeps a Sector Perform rating and $122 price target on Gilead (GILD) after hosting the RBC healthcare conference with a presentation by the company CMO. There was high management enthusiasm around anito-cel, the Tubulis platform, and potential path for and impact of once-yearly lenacapavir, though the I&I platform still sounds relatively early for investors to ascribe meaningful value to, with the firm also remaining more conservative on Trodelvy’s and Yeztugo’s long term opportunities, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead upgraded to Buy at Maxim on approaching growth drivers, valuation
- Gilead upgraded to Buy from Hold at Maxim
- Gilead Sciences Earnings Call Highlights Growth, Deal Drag
- Gilead to present new data on PBC, viral hepatitis at EASL 2026
- Gilead price target lowered to $168 from $175 at Morgan Stanley